

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/945,326	08/31/2001	Rachel Meyers	MPI00-344P1RM 2458	
30405	7590 - 12/14/2004		EXAMINER	
MILLENNIUM PHARMACEUTICALS, INC. 40 Landsdowne Street CAMBRIDGE, MA 02139			YU, MISOOK	
			ART UNIT	PAPER NUMBER
			1642	
		DATE MAILED: 12/14/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary						
		09/945,326	MEYERS ET AL.			
		Examiner	Art Unit			
		MISOOK YU, Ph.D.	1642			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠	Responsive to communication(s) filed on 23 S	September 2004.				
	This action is FINAL . 2b) This action is non-final.					
3)	,—					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 64-72 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 64 and 68-72 is/are rejected. 7) Claim(s) 65 - 67 is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.						
Applicati	on Papers					
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachmen	t(s)					
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
Paper No(s)/Mail Date. Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date. Notice of Informal Patent Application (PTO-152) Paper No(s)/Mail Date. Other:						

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 09/23/2004 has been entered.

The amendment filed on 03 September 2004 is acknowledged. Claims 64-72 are new, pending, and examined on merits.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.

All claims presented in the last Office action are cancelled, therefore the rejection stated in the previous Office action is moot.

This Office action contains new grounds of rejection.

The Following Are New Grounds of Rejections

Claim Rejections - 35 USC § 112

Claim68 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 68 depends on claim 64. It is not clear whether "the sample" in claim 68 further limits "a sample" in step i) or step iii).

Application/Control Number: 09/945,326

Art Unit: 1642

Claim 68 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This new matter rejection is made due to the limitation "a membrane-bound form of an isolated polypeptide". Applicant states that support for the new claims are found throughout the specification. However, the Office is not able to find the support in the specification as originally filed. Applicant is kindly requested to find the support in the specification as originally filed.

Claims 64, and 68-72 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an assay using an isolated SEQ ID NO:2 protein or a cell comprising SEQ ID NO:2 protein, does not reasonably provide enablement for an assay using a membrane-bound form of an isolated protein. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

The factors considered when determining if the disclosure satisfies the enablement requirement and whether any necessary experimentation is "undue" include, but are not limited to: 1) nature of the invention, 2) state of the prior art, 3) relative skill of those in the art, 4) level of predictability in the art, 5) existence of working examples, 6) breadth of claims, 7) amount of direction or guidance by the inventor, and

Application/Control Number: 09/945,326

Art Unit: 1642

8) quantity of experimentation needed to make or use the invention. *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

This scope of enablement rejection is made because the claims are interpreted as drawn to an assay using a membrane bound form of an isolated polypeptide.

The specification does not teach how to make a membrane bound form of an isolated polypeptide.

Voet et al., (Biochemistry, John Wileys &Sons, 1990, pages 284-289) teach that a membrane protein is modified with oligosaccharide or other molecules (note Fig. 11-21, for example). The specification only teaches the primary sequence of SEQ ID NO:2. It is noted that law requires that the disclosure of an application shall inform those skilled in the art how to make the alleged discovery, not how to screen it for themselves.

Considering the unpredictable state of art, limited guidance, no examples in the specification how to make the instantly claimed invention, it is concluded that undue experimentation is required to practice the invention.

Allowable Subject Matter

Claims 65-67are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU, Ph.D. whose telephone number is 571-

Art Unit: 1642

272-0839. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey C Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MISOOK YU, Ph.D. Examiner

Art Unit 1642